Active Recombinant Full Length Human MAPK1 Protein, GST-tagged

• Cat.No.: MAPK1-6912HF
• Product Overview: Full-length human Erk2 [1-360(end) amino acids of accession number NP_002736.3] was expressed as N- terminal GST-fusion protein (69 kDa) using E.coli expression system. GST-Erk2 was purified by using glutathione sepharose chromatography.

Specification

• Source: E. coli
• Species: Human
• Tag: GST
• Form: 50 mM Tris-HCl, 150 mM NaCl, 0.05% Brij35, 1 mM DTT, 10% glycerol, pH7.5
• Bio-activity: The activity was measured by off-chip mobility shift assay. The enzyme was incubated with fluorecence-labeled substrate and Mg(or Mn)/ATP. The phosphorylated and unphosphorylated substrates were separated and detected by LabChip™3000.
• Protein length: 1-360(end)
• Purity: 98%
• Applications: SDS-PAGE
• Storage: Store at -80C. Avoid repeating freeze-thaws.

Gene Information

• Gene Name: mitogen-activated protein kinase 1
• Official Symbol: MAPK1
• Synonyms: MAPK1;ERK;ERK-2;ERK2;ERT1;MAPK2;P42MAPK;PRKM1;PRKM2;p38;p40;p41;p41mapk;p42-MAPK
• Protein Refseq: NP_002736.3
• UniProt ID: P28482

Reviews

03/24/2022

Whether it be troubleshooting issues, offering experimental guidance, or addressing any concerns, the manufacturer's technical support ensures that researchers have a reliable and knowledgeable resource to rely on.

03/26/2021

In addition to its scientific merits, the manufacturer of MAPK1 protein stands out for its outstanding technical support.

03/11/2020

The company provides a dedicated team of experts who are readily available to assist researchers throughout their experimental journey.

Q&As

Can MAPK1 be used as a biomarker for cancer diagnosis?

MAPK1 expression and activity levels can be used as biomarkers to assess cancer risk and prognosis.

How can MAPK1 be targeted in drug development for non-cancer conditions?

MAPK1 inhibitors are being explored for potential use in non-cancer conditions, such as heart disease and neurodegenerative disorders.

In what other clinical conditions is MAPK1 relevant?

MAPK1 is also implicated in various other diseases, including cardiovascular diseases and neurological disorders.

Are there targeted therapies that inhibit MAPK1 for cancer treatment?

Yes, there are targeted therapies that aim to inhibit MAPK1, especially in cases where MAPK1 is overactive in cancer cells.

Can MAPK1 be used for personalized medicine approaches?

Yes, by assessing the MAPK1 status in a patient's cells, healthcare providers can develop personalized treatment plans.